December 22, 2010
The common shares of Abattis Biologix Corp. have been approved for listing on CNSX. The Company has 49,640,500 common shares outstanding all of which is held by the public.
Abattis Biologix is engaged in the research, development and manufacture of natural botanical formulations which prevent or treat various influenza strains found in human, avian and mammalian populations. On April 16, 2009, the Company entered into an agreement with PRB Pharmaceuticals, Inc. and Pacific Bio-Pharmaceuticals, Inc. for the purchase of their interest in patents and intellectual property related to anti viral products designed to prevent avian influenza in humans and poultry.
Listing and disclosure documents for Abattis Biologix Corp. will be available in the CNSX Listings Disclosure Hall.
Trading Date: Thursday, December 23, 2010
CUSIP: 00258E 10 8
ISIN: CA 00258E 10 8 8
Applications are being accepted for Market Makers for "FLU". If you have any questions or require further information please contact Radhika at (416) 572-2000 X 2435 or E-mail: email@example.com